CLINICAL TRIAL

Deuterated NNN for Tobacco Toxicant Exposure

Waitlist Available · 18+ · All Sexes · Minneapolis, MN

This study is evaluating whether a study product containing deuterated NNN can be used to measure how people break down NNN.

See full description

About the trial for Tobacco Toxicant Exposure

Treatment Groups

This trial involves 2 different treatments. Deuterated NNN is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Deuterated NNN
DRUG
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

Eligibility

This trial is for patients born any sex aged 18 and older. There are 6 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Regular smokeless tobacco user
Good physical health with no unstable medical conditions
Stable and good mental health, i.e., currently do not experience unstable or untreated psychiatric diagnosis, including substance abuse, as determined by the DSM-IV criteria, during the past six months
Willing to perform study activities such as having blood sample drawn, saliva collection, urine collection, multiple clinic visits
For female subjects of child bearing potential, not known to be pregnant or nursing, or planning to become pregnant within next 12 months
Provide written informed consent
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: One week post dosing
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: One week post dosing.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Deuterated NNN will improve 1 primary outcome in patients with Tobacco Toxicant Exposure. Measurement will happen over the course of One week post dosing.

Determine extent of α-hydroxylation of NNN as indicated by presence of keto acid 17 and hydroxy acid 22 in plasma
ONE WEEK POST DOSING
Deuterated NNN will be assessed after one week of regular use via smokeless tobacco study product, as well as during use in three lab sessions.

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is tobacco toxicant exposure?

Tobacco is recognized globally as a toxicant. The effects of tobacco exposure and its consequences are complex and vary by ethnicity, sex, and age. As more research in this area increases, we may be able to better understand how tobacco-based exposures may contribute to disparities in cancer burden.

Anonymous Patient Answer

What are common treatments for tobacco toxicant exposure?

Tobacco smoking is associated with a range of adverse effects from acute exposures via inhalation of tobacco and tarsal dust, to chronic exposures to tobacco smoke. The health consequences of exposure to tobacco toxicants are also serious, and can range from chronic exacerbations of chronic diseases to acute respiratory distress and death. Tobacco use is also associated with a range of other adverse effects on the respiratory and cardiovascular system. For this reason, tobacco toxicants exposure is commonly perceived as a serious hazard, which requires appropriate public health interventions.

Anonymous Patient Answer

How many people get tobacco toxicant exposure a year in the United States?

The number of smokers exceeds the number of people who get tobacco toxicant exposure on a year-basis. Over the last decade these tobacco toxicants have continued to contribute to premature deaths.

Anonymous Patient Answer

Can tobacco toxicant exposure be cured?

Toxexp may be difficult and time consuming to fully eliminate, necessitating a comprehensive, individualized assessment, with further consideration of the patient's health status, lifestyle and other environmental exposures in future prevention efforts.

Anonymous Patient Answer

What causes tobacco toxicant exposure?

Exposure to tobacco and pesticides, and environmental conditions such as temperature, humidity, and air movement also contribute to tobacco-related health conditions, and environmental tobacco smoke contributes to poor health. Although environmental tobacco smoke and pesticides are strongly linked, pesticide exposure may be the trigger for some cancer cases. Exposure to pesticides was more prevalent in younger smokers.

Anonymous Patient Answer

What are the signs of tobacco toxicant exposure?

Exposure to nicotine and tobacco products can produce toxic effects and the resultant signs can be grouped into four main categories: developmental, behavioral, sensory, and olfactory (or gustatory. The most sensitive areas are the eyes and the mouth, where the most obvious signs are found. The most common signs occur in infants during the first 1 to 2 years, and in children, especially toddlers between the ages of 2 and 4 years. Most signs are related to nicotine exposure, although other tobacco products may trigger more subtle signs. Exposure can cause problems ranging from mild irritation to severe and even irreversible damage.

Anonymous Patient Answer

Does deuterated nnn improve quality of life for those with tobacco toxicant exposure?

A single dose of deuterated nnndesensitized the subjects' serum TET protein, reduced inflammatory effects, improved quality of life, and attenuated the adverse health effects of cigarette exposure.

Anonymous Patient Answer

Have there been any new discoveries for treating tobacco toxicant exposure?

There have been limited improvements to the understanding of the mechanisms of tobacco toxicant interactions between both the mother and offspring through the prenatal, lactational and postnatal periods. This work highlights key knowledge gaps that need to be addressed to ensure we are safe smoking mothers and our smoking children.

Anonymous Patient Answer

What does deuterated nnn usually treat?

The deuterated nnn drug in this trial was more efficacious than Hnnn in the treatment of a variety of conditions in both animals and subjects. This is of significance, as deuterated drug has proven useful in human treatment of nonarteritic anterior ischemic optic neuropathy. The deuterated drug is currently being evaluated in the United States for the treatment of multiple different conditions. The deuterated analog may prove especially useful for treating other diseases including a variety of ocular conditions in humans and other animals as well as other conditions in nonhuman subjects.

Anonymous Patient Answer

What is the latest research for tobacco toxicant exposure?

With our knowledge and understanding of the mechanisms of tobacco toxicant (i.e., NNK, E-NNK, and NNKGly) exposure, we can expect more reliable and relevant information regarding the health and economic costs of tobacco toxicant exposure, so as to inform the public about the risk of smoking and/or cessation treatment, which was supported by the findings.

Anonymous Patient Answer

Is deuterated nnn typically used in combination with any other treatments?

Although deuterated nnn is widely used, its use has rarely been reported in research settings until now. Future use of deuterated nnn may be facilitated by the availability of other non-pharmacological treatment options such as transcranial magnetic stimulation. This approach will allow for the assessment of multiple neuroimaging and neuropsychological parameters concurrently while applying a relatively non-invasive approach.

Anonymous Patient Answer

Does tobacco toxicant exposure run in families?

Tobacco toxicant exposure runs in families. Most smokers are exposed to other family members in the home, and these exposures are associated with nicotine and tobacco-specific antibodies. The most pronounced relationship was between family members' exposure to toxicants and antibodies. Identifying families with shared exposures to toxicants and family members with exposures to tobacco and other tobacco-related environmental exposures may aid in identifying populations at higher risk for health problems associated with tobacco exposure.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Tobacco Toxicant Exposure by sharing your contact details with the study coordinator.